Trends and issues in characterizing early cognitive changes in Parkinson's disease

Current Neurology and Neuroscience Reports

Volumn 12, Issue 6, 2012, Pages 695-702

  Claassen, Daniel O ^a   Wylie, Scott A ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Action control; Mild cognitive impairment; Parkinson disease; Reward

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

ARTICLE; BRAIN DEPTH STIMULATION; COGNITIVE DEFECT; DECISION MAKING; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; DOPAMINERGIC TRANSMISSION; ELECTROENCEPHALOGRAM; EVENT RELATED POTENTIAL; HIGH RISK BEHAVIOR; HUMAN; LEARNING; MILD COGNITIVE IMPAIRMENT; MOTOR CONTROL; NERVE CELL NETWORK; NEUROPSYCHOLOGICAL TEST; OUTCOME ASSESSMENT; PARKINSON DISEASE; PREFRONTAL CORTEX; REWARD; TREND STUDY; WORKING MEMORY;

DECISION MAKING; EARLY DIAGNOSIS; HUMANS; LEARNING; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PSYCHOMOTOR PERFORMANCE;

EID: 84870521328     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-012-0312-5     Document Type: Article

References (71)

1. Hely MA, Reid WG, Adena MA, et al. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23(6):837-44.
2. Aarsland D, Bronnick K, Larsen JP, et al. Cognitive impairment in incident, untreated Parkinson disease: the Norwegian Park West study. Neurology. 2009;72(13):1121-6.
3. Caviness JN, Driver-Dunckley E, Connor DJ, et al. Defining mild cognitive impairment in Parkinson's disease. Mov Disord. 2007;22 (9):1272-7.
4. Janvin CC, Larsen JP, Aarsland D, Hugdahl K. Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia. Mov Disord. 2006;21(9):1343-9.
5. Dalrymple-Alford JC, Livingston L, MacAskill MR, et al. Characterizing mild cognitive impairment in Parkinson's disease. Mov Disord. 2011;26(4):629-36.
6. Fernandez HH, Crucian GP, Okun MS, et al. Mild cognitive impairment in Parkinson's disease: the challenge and the promise. Neuropsychiatr Dis Treatment. 2005;1(1):37-50.
7. Jellinger KA. Mild cognitive impairment in Parkinson disease: heterogenous mechanisms. J Neural Transm. 2012;
8. Litvan I, Goldman JG, Troster AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord. 2012;27(3):349-56.
9. Muslimovic D, Post B, Speelman JD, Schmand B. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology. 2005;65(8):1239-45.
10. Troster AI. A precis of recent advances in the neuropsychology of mild cognitive impairment(s) in Parkinson's Disease and a proposal of preliminary research criteria. J Int Neuropsychol Soc. 2011;1-14
11. Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56 (3):303-8.
12. Liepelt-Scarfone I, Graeber S, Feseker A, et al. Influence of different cut-off values on the diagnosis of mild cognitive impairment in Parkinson's disease. Parkinson's Dis. 2011;2011:540843.
13. Aarsland D, Bronnick K, Fladby T. Mild cognitive impairment in Parkinson's disease. Curr Neurol Neurosci Rep. 2011;11(4):371-8.
14. Cools R. Dopaminergic modulation of cognitive functionimplications for L-DOPA treatment in Parkinson's disease. Neurosci Biobehav Rev. 2006;30(1):1-23.
15. Cools R, D'Esposito M. Inverted-U-shaped dopamine actions on human working memory and cognitive control. Biol Psychiatry. 2011;69(12):e113-25.
16. Cools R, Barker RA, Sahakian BJ, Robbins TW. Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands. Cereb Cortex. 2001;11(12):1136-43.
17. Costa A, Peppe A, Dell'Agnello G, et al. Dopaminergic modulation of visual-spatial working memory in Parkinson's disease. Dement Geriatr Cogn Disord. 2003;15(2):55-66.
18. Wylie SA, Claassen DO, Huizenga HM, et al. Dopamine agonists and the suppression of impulsive motor actions in Parkinson disease. J Cog Neurosci. 2012;24(8):1709-24.
19. Obeso I, Wilkinson L, Jahanshahi M. Levodopa medication does not influence motor inhibition or conflict resolution in a conditional stop-signal task in Parkinson's disease. Exp Brain Res. 2011;213 (4):435-45.
20. Ridderinkhoff KR, Forstmann BU, Wylie SA, Burle B, van den Wildenberg WPM. Neurocognitive mechanisms of action control: resisting the call of the Sirens. Wiley Interdisciplinary Rev Cogn Sci. 2011;2:174-92.
21. Ridderinkhoff KR. Activation and suppression in conflict tasks: Empirical clarification through distributional analyses. In: Hommel WPB, editor. Common mechanisms in perception and action, attention, & performance. Oxford: Oxford University Press; 2002. p. 494-519.
22. Botvinick MM, Braver TS, Barch DM, et al. Conflict monitoring and cognitive control. Psychol Rev. 2001;108(3):624-52.
23. Gratton G, Coles MG, Donchin E. Optimizing the use of information: strategic control of activation of responses. J Exp Psychol Gen. 1992;121(4):480-506.
24. Aron AR. The neural basis of inhibition in cognitive control. Neuroscientist. 2007;13(3):214-28.
25. Casey BJ, Thomas KM, Welsh TF, Badgaiyan RD, Eccard CH, Jennings JR, et al. Dissociation of response conflict, attentional selection, and expectancy with functional magnetic resonance imaging. Proc Natl Acad Sci USA. 2000;97:8728-33.
26. Nee DE, Wager TD, Jonides J. Interference resolution: insights from a meta-analysis of neuroimaging tasks. Cogn Affect Behav Neurosci. 2007;7(1):1-17.
27. Davelaar EJ. A computational study of conflict-monitoring at two levels of processing: reaction time distributional analyses and hemodynamic responses. Brain Res. 2008;1202:109-19.
28. Forstmann BU, Jahfari S, Scholte HS, et al. Function and structure of the right inferior frontal cortex predict individual differences in response inhibition: a model-based approach. J Neurosci. 2008;28 (39):9790-6.
29. Forstmann BU, van den Wildenberg WP, Ridderinkhof KR. Neural mechanisms, temporal dynamics, and individual differences in interference control. J Cog Neurosci. 2008;20(10):1854-65.
30. Ridderinkhof KR, van den Wildenberg WP, Segalowitz SJ, Carter CS. Neurocognitive mechanisms of cognitive control: the role of prefrontal cortex in action selection, response inhibition, performance monitoring, and reward-based learning. Brain Cogn. 2004;56(2):129-40.
31. Eriksen BA, Eriksen CW. Effects of noise letters upon the identification of target letters in a non-search task. Percept Psychophys. 1974;16(1974):143-9.
32. Simon Jr. Reactions toward the source of stimulation. J Exp Psychol. 1969;81(1):174-6.
33. Simon Jr. The effects of an irrelevant directional cue on human information processing. In: Proctor RW, Reeve TG, editors. Stimulus-response compatibility: An integrated perspective. Amsterdam: North-Holland; 1990. p. 31-63.
34. van den Wildenberg WP, Wylie SA, Forstmann BU, et al. To head or to heed? Beyond the surface of selective action inhibition: a review. Front Hum Neurosci. 2010;4:222.
35. Praamstra P, Stegeman DF, Cools AR, Horstink MW. Reliance on external cues for movement initiation in Parkinson's disease. Evidence from movement-related potentials. Brain. 1998;121(Pt 1):167-77.
36. Wylie SA, Stout JC, Bashore TR. Activation of conflicting responses in Parkinson's disease: evidence for degrading and facilitating effects on response time. Neuropsychologia. 2005;43 (7):1033-43.
37. Wylie SA, van den Wildenberg WP, Ridderinkhof KR, et al. The effect of Parkinson's disease on interference control during action selection. Neuropsychologia. 2009;47(1):145-57.
38. Wylie SA, Ridderinkhof KR, Bashore TR, van den Wildenberg WP. The effect of Parkinson's disease on the dynamics of on-line and proactive cognitive control during action selection. J Cogn Neurosci. 2010;22(9):2058-73.
39. Wylie SA, van den Wildenberg WP, Ridderinkhof KR, et al. The effect of speed-accuracy strategy on response interference control in Parkinson's disease. Neuropsychologia. 2009;47(8-9):1844-53.
40. Logan GD, Cowan WB, Davis KA. On the ability to inhibit simple and choice reaction time responses: a model and a method. J Exp Psychol Hum Percept Perform. 1984;10(2):276-91.
41. Gauggel S, Rieger M, Feghoff TA. Inhibition of ongoing responses in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 2004;75(4):539-44.
42. van den Wildenberg WP, van Boxtel GJ, van der Molen MW, et al. Stimulation of the subthalamic region facilitates the selection and inhibition of motor responses in Parkinson's disease. J Cog Neurosci. 2006;18(4):626-36.
43. Bonnin CA, Houeto JL, Gil R, Bouquet CA. Adjustments of conflict monitoring in Parkinson's disease. Neuropsychology. 2010;24(4):542-6.
44. Fielding J, Georgiou-Karistianis N, Bradshaw J, et al. No sequence dependent modulation of the Simon effect in Parkinson's disease. Brain Res Cogn Brain Res. 2005;25(1):251-60.
45. Praamstra P, Plat FM. Failed suppression of direct visuomotor activation in Parkinson's disease. J Cog Neurosci. 2001;13 (1):31-43.
46. Falkenstein M, Hoormann J, Christ S, Hohnsbein J. ERP components on reaction errors and their functional significance: a tutorial. Biol Psychol. 2000;51(2-3):87-107.
47. Gehring WJ, Goss B, Coles MGH, Meyer DE, Donchin E. A neural system for error detection and compensation. Psychol Sci. 1993;4(1993):385-90.
48. Holroyd CB, Coles MG. The neural basis of human error processing: reinforcement learning, dopamine, and the error-related negativity. Psychol Rev. 2002;109(4):679-709.
49. Stemmer B, Segalowitz SJ, Dywan J, et al. The error negativity in nonmedicated and medicated patients with Parkinson's disease. Clin Neurophysiol. 2007;118(6):1223-9.
50. Willemssen R, Muller T, Schwarz M, et al. Error processing in patients with Parkinson's disease: the influence of medication state. J Neural Transm. 2008;115(3):461-8.
51. Wylie SA, Ridderinkhof KR, Elias WJ, et al. Subthalamic nucleus stimulation influences expression and suppression of impulsive behaviour in Parkinson's disease. Brain. 2010;133 (Pt 12):3611-24.
52. Vandenbossche J, Deroost N, Soetens E, et al. Freezing of gait in Parkinson disease is associated with impaired conflict resolution. Neurorehabil Neural Repair. 2011;25(8):765-73.
53. Wylie S, van den Wildenberg WPM, Ridderinkhof KR, et al. Differential susceptibility to motor impulsivity among functional subtypes of Parkinson's disease. J Neurol Neurosurg Psychiatry. (In press)
54. Schultz W. Dopamine neurons and their role in reward mechanisms. Curr Opin Neurobiol. 1997;7(2):191-7.
55. Hirsch E, Graybiel AM, Agid YA. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature. 1988;334(6180):345-8.
56. Manes F, Sahakian B, Clark L, et al. Decision-making processes following damage to the prefrontal cortex. Brain. 2002;125(Pt 3):624-39.
57. Bechara A. Neurobiology of decision-making: risk and reward. Semin Clin Neuropsychiatry. 2001;6(3):205-16.
58. Poletti M, Frosini D, Lucetti C, et al. Iowa Gambling Task in de novo Parkinson's disease: a comparison between good and poor performers. Mov Disord. 2012;27(2):331-2.
59. Ibarretxe-Bilbao N, Junque C, Tolosa E, et al. Neuroanatomical correlates of impaired decision-making and facial emotion recognition in early Parkinson's disease. Eur J Neurosci. 2009;30 (6):1162-71.
60. Perretta JG, Pari G, Beninger RJ. Effects of Parkinson disease on two putative nondeclarative learning tasks: probabilistic classification and gambling. Cogn Behav Neurol. 2005;18(4):185-92.
61. Deister CA, Teagarden MA, Wilson CJ, Paladini CA. An intrinsic neuronal oscillator underlies dopaminergic neuron bursting. J Neurosci. 2009;29(50):15888-97.
62. Schott BH, Minuzzi L, Krebs RM, et al. Mesolimbic functional magnetic resonance imaging activations during reward anticipation correlate with reward-related ventral striatal dopamine release. J Neurosci. 2008;28(52):14311-9.
63. Frank MJ, Seeberger LC, O'Reilly RC. By carrot or by stick: cognitive reinforcement learning in parkinsonism. Science. 2004;306 (5703):1940-3.
64. Graef S, Biele G, Krugel LK, et al. Differential influence of levodopa on reward-based learning in Parkinson's disease. Front Hum Neurosci. 2010;4:169.
65. Voon V, Sohr M, Lang AE, et al. Impulse control disorders in Parkinson disease: a multicenter case-control study. Ann Neurol. 2011;69(6):986-96.
66. Claassen DO, van den Wildenberg WP, Ridderinkhof KR, et al. The risky business of dopamine agonists in Parkinson disease and impulse control disorders. Behav Neurosci. 2011;125(4):492-500.
67. Martinez-Horta S, Kulisevsky J. Is all cognitive impairment in Parkinson's disease "mild cognitive impairment"? J Neuroal Transm. 2011;118(8):1185-90.
68. Voon V, Reynolds B, Brezing C, et al. Impulsive choice and response in dopamine agonist-related impulse control behaviors. Psychopharm. 2010;207(4):645-59.
69. Zgaljardic DJ, Borod JC, Foldi NS, Mattis P. A review of the cognitive and behavioral sequelae of Parkinson's disease: relationship to frontostriatal circuitry. Cogn Behav Neurol. 2003;16 (4):193-210.
70. Zgaljardic DJ, Borod JC, Foldi NS, et al. An examination of executive dysfunction associated with frontostriatal circuitry in Parkinson's disease. J Clin Exp Neuropsychol. 2006;28(7):1127-4.
71. Kahn E, D'Haese PF, Dawant B, et al. Deep brain stimulation in early stage Parkinson's disease: operative experience from a prospective randomised randomized clinical trial. J Neurol Neurosurg Psychiatry. 2012;83(2):164-70.